drugset / Trial / NCT00612651
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Objectives: To determine maximum tolerated dose of farnesyl transferase inhibitor, SCH 66336, when administered w TEMODAR®. To characterize any toxicity associated w combo of farnesyl transferase inhibitor, SCH 66336, \& TEMODAR®. To observe patients for clinical antitumor response when treated with combination of farnesyl transferase inhibitor, SCH 66336, \& TEMODAR®. To assess pharmacokinetics of SCH 66336 for patients on \& not on enzyme inducing antiepileptic drugs.
Timeline
- Start
- 2005-10
- Primary completion
- 2009-01
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lonafarnib | Small molecule | 75 mg | Oral |
| Subject | Lonafarnib | Small molecule | 125 mg | Oral |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |